NASDAQ:SKYE Skye Bioscience (SKYE) Stock Price, News & Analysis $4.58 +0.41 (+9.71%) Closing price 07/3/2025 03:56 PM EasternExtended Trading$4.58 0.00 (0.00%) As of 07/3/2025 04:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Skye Bioscience Stock (NASDAQ:SKYE) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Skye Bioscience alerts:Sign Up Key Stats Today's Range$4.06▼$4.6550-Day Range$1.98▼$4.5852-Week Range$1.14▼$7.47Volume947,978 shsAverage Volume498,649 shsMarket Capitalization$141.73 millionP/E RatioN/ADividend YieldN/APrice Target$16.60Consensus RatingBuy Company Overview Skye Bioscience, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100 used in the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy. It has license agreement with university of Mississippi. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. The company is headquartered in San Diego, California. Read More Skye Bioscience Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks45th Percentile Overall ScoreSKYE MarketRank™: Skye Bioscience scored higher than 45% of companies evaluated by MarketBeat, and ranked 522nd out of 922 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingSkye Bioscience has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageSkye Bioscience has only been the subject of 2 research reports in the past 90 days.Read more about Skye Bioscience's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Skye Bioscience are expected to decrease in the coming year, from ($1.04) to ($1.18) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Skye Bioscience is -5.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Skye Bioscience is -5.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSkye Bioscience has a P/B Ratio of 2.03. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted15.79% of the float of Skye Bioscience has been sold short.Short Interest Ratio / Days to CoverSkye Bioscience has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Skye Bioscience has recently decreased by 9.32%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSkye Bioscience does not currently pay a dividend.Dividend GrowthSkye Bioscience does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted15.79% of the float of Skye Bioscience has been sold short.Short Interest Ratio / Days to CoverSkye Bioscience has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Skye Bioscience has recently decreased by 9.32%, indicating that investor sentiment is improving significantly. News and Social Media2.5 / 5News Sentiment0.55 News SentimentSkye Bioscience has a news sentiment score of 0.55. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Skye Bioscience this week, compared to 3 articles on an average week.Search Interest17 people have searched for SKYE on MarketBeat in the last 30 days. This is an increase of 467% compared to the previous 30 days.MarketBeat Follows3 people have added Skye Bioscience to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Skye Bioscience insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.50% of the stock of Skye Bioscience is held by insiders.Percentage Held by InstitutionsOnly 21.09% of the stock of Skye Bioscience is held by institutions.Read more about Skye Bioscience's insider trading history. Receive SKYE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Skye Bioscience and its competitors with MarketBeat's FREE daily newsletter. Email Address SKYE Stock News HeadlinesSkye Bioscience Highlights Nimacimab’s Promise in Obesity Treatment, Anticipates Phase 2a DataJuly 6 at 9:51 AM | msn.comSkye Bioscience, Inc. (NASDAQ:SKYE) Receives $16.60 Average Price Target from BrokeragesJuly 6 at 4:19 AM | americanbankingnews.comWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon bring Elon Musk's DOGE operation to its final, dramatic conclusion - with huge consequences for millions of investors. So if you have any money in the market... you're almost out of time to prepare. This plan has already been put in place... and can operate even if Elon's long gone from Washington. July 6 at 2:00 AM | Altimetry (Ad)Skye Bioscience (NASDAQ:SKYE) Given "Market Outperform" Rating at JMP SecuritiesJune 26, 2025 | americanbankingnews.comPositive week for Skye Bioscience, Inc. (NASDAQ:SKYE) institutional investors who lost 53% over the past yearJune 25, 2025 | finance.yahoo.comSkye Bioscience Shares Nimacimab “Anatomy of Progress” Video Series and Highlights Preclinical CB1 Antibody Data Presented at the American Diabetes ... - MorningstarJune 24, 2025 | morningstar.comMSkye Bioscience Launches "Anatomy of Progress" Video Series on Nimacimab Development for Obesity Treatment - NasdaqJune 24, 2025 | nasdaq.comSkye Bioscience Shares Nimacimab “Anatomy of Progress” Video Series and Highlights Preclinical CB1 Antibody Data Presented at the American Diabetes Association's 85th Scientific SessionsJune 23, 2025 | globenewswire.comSee More Headlines SKYE Stock Analysis - Frequently Asked Questions How have SKYE shares performed this year? Skye Bioscience's stock was trading at $2.83 at the beginning of the year. Since then, SKYE shares have increased by 61.7% and is now trading at $4.5750. How were Skye Bioscience's earnings last quarter? Skye Bioscience, Inc. (NASDAQ:SKYE) issued its quarterly earnings results on Thursday, May, 8th. The company reported ($0.28) earnings per share for the quarter, topping analysts' consensus estimates of ($0.31) by $0.03. Read the conference call transcript. How do I buy shares of Skye Bioscience? Shares of SKYE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Skye Bioscience own? Based on aggregate information from My MarketBeat watchlists, some other companies that Skye Bioscience investors own include Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM), Netflix (NFLX), Tesla (TSLA) and Alphabet (GOOG). Company Calendar Last Earnings5/08/2025Today7/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:SKYE Previous SymbolNASDAQ:SKYE CIK1516551 Webskyebioscience.com Phone858-410-0266FaxN/AEmployees11Year FoundedN/APrice Target and Rating Average Stock Price Target$16.60 High Stock Price Target$20.00 Low Stock Price Target$14.00 Potential Upside/Downside+262.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)($0.82) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$26.57 million Net MarginsN/A Pretax MarginN/A Return on Equity-53.92% Return on Assets-48.58% Debt Debt-to-Equity RatioN/A Current Ratio11.85 Quick Ratio11.85 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.25 per share Price / Book2.03Miscellaneous Outstanding Shares30,980,000Free Float29,581,000Market Cap$141.73 million OptionableOptionable Beta1.95 20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free Report This page (NASDAQ:SKYE) was last updated on 7/6/2025 by MarketBeat.com Staff From Our PartnersThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredTrump's ticking time bombA looming tariff deadline on July 9th could be the spark — but what’s buried inside a recent White House docum...Porter & Company | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredWhy Elon is funding the “Quantum Power Grid”Elon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | SponsoredGold buying hits 4-year highThe perfect gold play right now? (currently under $10) Everything in the news now lines up perfectly for an...Stansberry Research | SponsoredThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Skye Bioscience, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Skye Bioscience With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.